Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Inspirational Quest to Eradicate Cancer

The world-renowned Thoracic Oncologist, Dr. Gerold Bepler, joined I Don’t Care’s Kevin Stevenson for a conversation that was no less than inspirational. Dr. Bepler, President and CEO of the Karmanos Cancer Institute, has a mission; to eradicate cancer. It’s more than a dream for Dr. Bepler; he believes it will be a reality one day….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

The world-renowned Thoracic Oncologist, Dr. Gerold Bepler, joined I Don’t Care’s Kevin Stevenson for a conversation that was no less than inspirational. Dr. Bepler, President and CEO of the Karmanos Cancer Institute, has a mission; to eradicate cancer. It’s more than a dream for Dr. Bepler; he believes it will be a reality one day.

Dr. Bepler arrived from Germany to the United States in 1983. Following a post-doctoral fellowship at the National Cancer Institute, the starting point for his journey into lung cancer research. This career path took Dr. Bepler through many stops along the way, and in 2010 he joined the Karmanos Cancer Institute.

The mission to eradicate cancer got a boost in 1971 with the National Cancer Act, and Dr. Bepler said there’s tremendous progress towards this goal since that point. “People now diagnosed with cancer have hope,” Dr. Bepler said. “And many of them get cured of the disease and have a good quality of life. That all wouldn’t have been possible without the National Cancer Act.”

Much of the progress made to eradicating cancer at the Karmanos Cancer Institute owes a debt of gratitude to that 50-year-old law for providing necessary funding that makes such research possible.

“The Karmanos Cancer Institute became one of the NCI designated cancer centers,” Dr. Bepler said. “Very quickly, the National Cancer Institute realized just having one cancer institute in Bethesda, Maryland alone wouldn’t be able to achieve that high goal of eradicating cancer. This network established cancer centers throughout the United States.” What started as a couple of centers in the 1970s is now more than 50 comprehensive cancer centers.

The world now possesses many drugs and treatments to treat cancer through the dedication and research of institutes like the Karmanos Center. And some research led to treatments for other diseases. Dr. Bepler mentioned the Karmanos Center developed three of the first FDA-approved AIDS drugs.

More Like This Story:

The Rising Tide of Food Allergens

From an Idea to Billion Dollar Company: How a Doctor Lobbied DC for HSAs

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512